| answer text |
<p>The preliminary efficacy data is positive and indicates that the University of
Oxford / AstraZeneca vaccine is 70.4% effective across two different dosage regimens.
One of these dose regimens could be up to 90% effective.</p><p>To beat this pandemic,
it has always been likely that we would need more than one vaccine. We have now seen
excellent results with multiple vaccine candidates. There will be variations between
the vaccines in how well they work for different population subgroups and how long
the protection lasts, alongside other factors.</p><p>The University of Oxford / AstraZeneca
vaccine has the distinct advantage that it can be stored at fridge temperature, making
it easier to transport and distribute globally than other Covid-19 vaccines. The fact
that the vaccine has been manufactured by AstraZeneca at cost also means it is affordable,
potentially making this UK-developed vaccine a vaccine for the world.</p><p>The Vaccine
TaskForce’s portfolio includes different types of vaccine and we continue to keep
the portfolio under review.</p>
|
|
